2023
TP53 Mutation-driven Stratified Mucin-producing Carcinoma Coexisting With Squamous Cell Carcinoma of the Vulva: A Case Study
Wadia R, McHenry A, Abi-Raad R, Hui P. TP53 Mutation-driven Stratified Mucin-producing Carcinoma Coexisting With Squamous Cell Carcinoma of the Vulva: A Case Study. International Journal Of Gynecological Pathology 2023, 42: 555-560. PMID: 37255422, DOI: 10.1097/pgp.0000000000000961.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma in SituCarcinoma, Squamous CellFemaleHumansLichen Sclerosus et AtrophicusMiddle AgedMucinsMutationTumor Suppressor Protein p53VulvaVulvar NeoplasmsConceptsSquamous cell carcinomaInvasive squamous cell carcinomaVulvar intraepithelial neoplasiaCell carcinomaIntraepithelial neoplasiaLichen sclerosusAssociated with high-risk human papillomavirus infectionHigh-risk human papillomavirus infectionDifferentiated vulvar intraepithelial neoplasiaPresence of lymphovascular invasionInguinal lymph node metastasisHuman papillomavirus infectionVulvar lichen sclerosusMucin-producing carcinomaLymph node metastasisIntraepithelial lesionsLymphovascular invasionTP53 mutationsNode metastasisPapillomavirus infectionNeoplastic componentsCarcinomaUnique caseTP53Sclerosus
2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaSacituzumab govitecanTrop-2 expressionAntibody-drug conjugatesCell surface markersXenograft modelTrop-2Adenocarcinoma/adenosquamous carcinomaAnti-Trop-2 antibodyCell linesWeekly intravenous administrationSignificant tumor growth inhibitionCervical cancer patientsPrimary cervical cancerStrong diffuse stainingPrimary cervical tumorsCervical cancer cell linesEpithelial solid tumorsReal-time polymerase chain reactionTumor growth inhibitionHuman placental tissuePositive cell linesNegative cell linesVivo antitumor activityCancer cell lines
2013
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal Of Clinical And Experimental Pathology 2013, 6: 1880-9. PMID: 24040454, PMCID: PMC3759496.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDNA Mutational AnalysisErbB ReceptorsExonsFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingHumansLung NeoplasmsMaleMiddle AgedMutationParaffin EmbeddingPhenotypePolymerase Chain ReactionPrecision MedicinePredictive Value of TestsPressurePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTissue FixationYoung AdultConceptsNon-small cell lung carcinomaCore needle biopsyCell lung carcinomaKRAS mutationsNSCLC patientsSurgical resectionEGFR mutationsLung carcinomaNeedle biopsyKRAS mutation analysisTyrosine kinase inhibitorsKRAS gene mutationsDirect sequencingMutation analysisFemale patientsAdenocarcinoma componentLung cancerPatientsEGFRExon 19Kinase inhibitorsExon 18Gene mutationsStatistical significanceResection
2011
Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions
Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions. Cancer Cytopathology 2011, 119: 228-234. PMID: 21732551, DOI: 10.1002/cncy.20172.Peer-Reviewed Original ResearchConceptsLow-grade squamous intraepithelial lesionsHR-HPV testingHPV testingCIN 2Colposcopy rateHR-HPVRelative light units/cutoffCervical intraepithelial neoplasia 2High-risk human papillomavirusHR-HPV statusRLU/COIntraepithelial neoplasia 2Hybrid Capture 2Squamous intraepithelial lesionsCIN 1 lesionsLarge teaching hospitalNegative predictive valueLSIL cytologyHPV statusIntraepithelial lesionsCapture 2Human papillomavirusTeaching hospitalCytologic diagnosisSevere lesions
2008
Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping
Xu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, Squamous CellComparative Genomic HybridizationDiagnosis, DifferentialEndometrial NeoplasmsEpithelioid CellsFemaleGene Expression Regulation, NeoplasticGenetic TestingGenotypeGestational Trophoblastic DiseaseHumansItalyLung NeoplasmsMiddle AgedPregnancyUnited StatesUterine Cervical NeoplasmsConceptsEpithelioid trophoblastic tumorTrophoblastic tumorSquamous cell carcinomaUterine cervixComparative genomic hybridizationCommon squamous cell carcinomaChromosomal alterationsInvasive squamous cell carcinomaChorionic-type intermediate trophoblastGestational trophoblastic diseaseGenomic hybridizationDNA genotypingIntermediate trophoblastTrophoblastic diseaseAnatomic locationComparative genomic hybridization analysisTrophoblastic originTumorsGenomic hybridization analysisCervixNormal tissuesTrophoblastic natureConventional comparative genomic hybridizationCarcinomaChromosomal profile